Login
Companies $XENE
$39.05 -$0.21 (0.53%) After hours
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc.

xenon-pharma.com

What Do They Do?

Discovers and develops drug candidates for epilepsy, depression and pain for patients with neurological and psychiatric disorders.

How Do They Make Money?

Collaboration partners pay for licenses and research and development services; agreements may provide upfront payments, research funding, milestone payments and royalties.

FY2025 revenue

Who Are Their Customers?

Collaboration partners and licensees provide research funding and may receive licenses or research and development services under collaboration agreements.

Do Revenues Turn Into Profits?

No. It lost $345.9M in FY2025.

Operating income, FY2025
−4974% of revenue
▼ −34% (Loss) vs FY2024 (−$279.3M)
Net income, FY2025
−4612% of revenue
▼ −48% (Loss) vs FY2024 (−$234.3M)
Free cash flow, FY2025
−3732% of revenue
▼ −52% (Loss) vs FY2024 (−$184.5M)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
vs $0 in Q3 FY2025
Net income
▼ −21% (Loss)
vs −$90.9M in Q3 FY2025

Shrinking. Revenue fell 59% in 4 years, from $18.4M in FY2021 to $7.5M in FY2025, about 20% a year.

Broader mood-disorder work The older report described an MDD program; the latest report also describes azetukalner development for bipolar depression.

Pain drug candidates The earlier report described the pipeline as focused on epilepsy; the latest report also describes potassium- and sodium-channel drug candidates being developed for pain.

Who Do They Compete With?

Competes with Biohaven, Jazz Pharmaceuticals, Neurona Therapeutics, NeuShen Therapeutics, Otsuka Pharmaceutical, Praxis Precision Medicines, QurAlis, Rapport Therapeutics, SK Life Science, Supernus Pharmaceuticals, Zhimeng Biopharma, AbbVie, Alto Neuroscience, Axsome Therapeutics, Johnson & Johnson, Neumora Therapeutics, Neurocrine Biosciences, Vanda Pharmaceuticsals, Autobahn Therapeutics, and Eli Lilly and

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support